Literature DB >> 12121967

Hematologic effects of linezolid: summary of clinical experience.

Stanton L Gerson1, Sheldon L Kaplan, Jon B Bruss, Vu Le, Felix M Arellano, Barry Hafkin, David J Kuter.   

Abstract

Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at > or =2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12121967      PMCID： PMC127358          DOI： 10.1128/AAC.46.8.2723-2726.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Linezolid and reversible myelosuppression.

Authors:  S L Green; J C Maddox; E D Huttenbach
Journal:  JAMA       Date:  2001-03-14       Impact factor: 56.272

Review 2.  Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid.

Authors:  D J Kuter; G S Tillotson
Journal:  Pharmacotherapy       Date:  2001-08       Impact factor: 4.705

Review 3.  Hematological complications of antiinfectious agents.

Authors:  P Beris; P A Miescher
Journal:  Semin Hematol       Date:  1988-04       Impact factor: 3.851

4.  Platelet-mediated bleeding caused by broad-spectrum penicillins.

Authors:  R J Fass; E A Copelan; J T Brandt; M L Moeschberger; J J Ashton
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

Review 5.  Adverse reactions associated with the use of oral penicillins and cephalosporins.

Authors:  A Alanis; A J Weinstein
Journal:  Med Clin North Am       Date:  1983-01       Impact factor: 5.456

6.  In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.

Authors:  G A Noskin; F Siddiqui; V Stosor; D Hacek; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

7.  Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.

Authors:  Dennis L Stevens; Daniel Herr; Harry Lampiris; John Lee Hunt; Donald H Batts; Barry Hafkin
Journal:  Clin Infect Dis       Date:  2002-05-13       Impact factor: 9.079

8.  Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.

Authors:  D L Stevens; L G Smith; J B Bruss; M A McConnell-Martin; S E Duvall; W M Todd; B Hafkin
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 9.  Drug-induced anaemias.

Authors:  R H Girdwood
Journal:  Drugs       Date:  1976       Impact factor: 9.546

10.  Nafcillin-induced platelet dysfunction and bleeding.

Authors:  D P Alexander; M E Russo; D E Fohrman; G Rothstein
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191
View more
  86 in total

Review 1.  Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?

Authors:  Steven Y C Tong; Luke F Chen; Vance G Fowler
Journal:  Semin Immunopathol       Date:  2011-12-11       Impact factor: 9.623

2.  Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.

Authors:  J W C Alffenaar; T van der Laan; S Simons; T S van der Werf; P J van de Kasteele; H de Neeling; D van Soolingen
Journal:  Antimicrob Agents Chemother       Date:  2011-01-03       Impact factor: 5.191

3.  Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones.

Authors:  E E McKee; M Ferguson; A T Bentley; T A Marks
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Case studies in anticoagulation management.

Authors:  Wendy A Leong
Journal:  J Thromb Thrombolysis       Date:  2007-10-01       Impact factor: 2.300

5.  Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation.

Authors:  Shankar S Iyer; Qiong He; John R Janczy; Suzanne L Cassel; Fayyaz S Sutterwala; Eric I Elliott; Zhenyu Zhong; Alicia K Olivier; Jeffrey J Sadler; Vickie Knepper-Adrian; Renzhi Han; Liang Qiao; Stephanie C Eisenbarth; William M Nauseef
Journal:  Immunity       Date:  2013-08-15       Impact factor: 31.745

6.  Risk factors for thrombocytopenia in adult chinese patients receiving linezolid therapy.

Authors:  Chao Chen; Dai-Hong Guo; Xiutang Cao; Yun Cai; Yuanjie Xu; Man Zhu; Liang Ma
Journal:  Curr Ther Res Clin Exp       Date:  2012-12

7.  Pediatric anthrax clinical management.

Authors:  John S Bradley; Georgina Peacock; Steven E Krug; William A Bower; Amanda C Cohn; Dana Meaney-Delman; Andrew T Pavia
Journal:  Pediatrics       Date:  2014-05       Impact factor: 7.124

8.  Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid.

Authors:  Alex Soriano; Mar Ortega; Sebastián García; Georgina Peñarroja; Albert Bové; Miguel Marcos; Juan C Martínez; José A Martínez; Josep Mensa
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

Review 9.  The Enterococcus: a Model of Adaptability to Its Environment.

Authors:  Mónica García-Solache; Louis B Rice
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

Review 10.  Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

Authors:  George G Zhanel; Grace Sniezek; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2009       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.